18.09.03 · organismal-bio / reproductive

Fertilization and early development: implantation, HCG signaling, and placental formation

stub3 tiersLean: nonepending prereqs

Anchor (Master): Guyton, A. C. & Hall, J. E. — Textbook of Medical Physiology, 14th ed. (2021), Ch. 82-83

Intuition Beginner

Fertilization occurs when a single sperm penetrates an egg in the fallopian tube. Of the 200--500 million sperm released into the vagina during intercourse, only a few hundred reach the egg in the ampulla of the fallopian tube. The rest are lost to vaginal acidity, cervical mucus filtering, phagocytosis by immune cells, and wrong turns into the wrong fallopian tube. Exactly one sperm fuses with the egg; the egg then immediately locks out all others.

The fertilized egg, now called a zygote, begins dividing as it travels toward the uterus over the next 3--5 days. By the time it reaches the uterus, it has become a hollow ball of cells called a blastocyst. About 6--7 days after fertilization, the blastocyst implants into the thickened uterine lining (endometrium).

Once implanted, the embryo produces human chorionic gonadotropin (HCG) -- the hormone detected by pregnancy tests. HCG signals the ovary to keep the corpus luteum alive, which continues secreting progesterone to maintain the uterine lining. Without HCG, the corpus luteum would degenerate, progesterone would drop, and the uterine lining would be shed -- ending the pregnancy before it could be established.

Over the following weeks, the placenta forms as a joint structure between embryonic and maternal tissues. It becomes the baby's lungs (gas exchange), gut (nutrient transfer), and kidneys (waste removal) for the duration of pregnancy. The placenta also takes over progesterone and estrogen production from the corpus luteum by 10--12 weeks, making the pregnancy self-sustaining.

Visual Beginner

Timeline of early development:

Day post-fertilization	Event	Location
0	Fertilization	Ampulla of fallopian tube
1--2	First cleavages (2-cell, 4-cell)	Fallopian tube
3	Morula (16--32 cells)	Fallopian tube / entering uterus
4--5	Blastocyst formation	Uterine cavity
6--7	Implantation begins	Uterine endometrium
8--10	Implantation completes	Endometrium
10--12	HCG detectable in maternal blood	--
14	HCG detectable in urine (pregnancy test)	--
4--5 weeks	Placental circulation established	Uterus
10--12 weeks	Placenta takes over progesterone production	Uterus

Worked example Beginner

Trace the critical events from ovulation to a positive pregnancy test:

Day 0 (ovulation). The secondary oocyte is released from the ovary and picked up by the fimbriae of the fallopian tube. It begins traveling toward the uterus.
Day 0--1 (fertilization). Sperm that have survived the journey through the cervix, uterus, and fallopian tube encounter the egg in the ampulla. One sperm penetrates the zona pellucida (the egg's outer coat), fuses with the egg membrane, and triggers the cortical reaction, which hardens the zona pellucida to block all other sperm. The sperm's nucleus and the egg's nucleus (each carrying 23 chromosomes) fuse to form a single 46-chromosome zygote.
Days 1--3 (cleavage). The zygote undergoes rapid mitotic divisions -- 2 cells, 4 cells, 8 cells, 16 cells -- while still enclosed in the zona pellucida. The total mass does not increase; the cells simply get smaller. By day 3, it is a solid ball called a morula.
Days 4--5 (blastocyst formation). The morula develops a fluid-filled cavity, becoming a blastocyst: a hollow sphere with an outer layer (trophoblast, which will form the placenta) and an inner cluster of cells (inner cell mass, which will form the embryo). The blastocyst hatches from the zona pellucida.
Days 6--7 (implantation). The blastocyst attaches to the endometrium and begins to burrow in. The trophoblast cells begin producing HCG almost immediately.
Days 10--14 (HCG rises). HCG enters the maternal bloodstream. By day 10--12 it is detectable in blood; by day 14 (about the time a missed period would be noticed) it is detectable in urine. A home pregnancy test detects HCG in urine and turns positive.
Weeks 4--12 (placental development). The trophoblast differentiates and invades the endometrium, forming chorionic villi bathed in maternal blood. The corpus luteum, sustained by HCG, produces progesterone until the placenta is mature enough to take over at 10--12 weeks.

Check your understanding Beginner

Formal definition Intermediate+

Fertilization: capacitation and the acrosome reaction

Freshly ejaculated sperm cannot fertilize an egg. They must undergo capacitation -- a series of functional changes that occur in the female reproductive tract over several hours. Capacitation involves:

Removal of cholesterol from the sperm plasma membrane, increasing membrane fluidity and calcium permeability.
Removal of glycoproteins deposited by seminal plasma that coat the sperm surface.
Alkalinization of sperm intracellular pH, activating calcium channels and increasing flagellar beat frequency (hyperactivation).
Protein phosphorylation cascades that prime the sperm for the acrosome reaction.

Capacitated sperm bind to ZP3, a glycoprotein component of the zona pellucida (the egg's glycoprotein coat, composed of ZP1, ZP2, and ZP3). ZP3 binding triggers the acrosome reaction:

The sperm plasma membrane fuses with the outer acrosomal membrane, forming pores through which acrosomal enzymes (hyaluronidase, acrosin) are released.
These enzymes digest a path through the zona pellucida.
The acrosome-reacted sperm, now exposing its inner acrosomal membrane (which bears the protein IZUMO1), penetrates through the zona pellucida and reaches the egg plasma membrane (oolemma).
IZUMO1 on the sperm binds to JUNO (also called folate receptor 4) on the egg surface, mediating sperm-egg membrane fusion.
The sperm nucleus enters the oocyte cytoplasm.

The cortical reaction and polyspermy block

Fusion of the first sperm with the egg triggers the cortical reaction, which prevents polyspermy (fertilization by more than one sperm):

Sperm fusion activates phospholipase C in the egg, generating IP3.
IP3 triggers a massive release of calcium from the endoplasmic reticulum -- a calcium wave that propagates across the egg over 2--3 minutes.
The calcium surge causes cortical granules (vesicles at the egg periphery) to fuse with the plasma membrane and release their contents into the perivitelline space.
Cortical granule enzymes modify ZP2 and ZP3 in the zona pellucida, causing the zona to harden (the zona reaction) and destroying sperm-binding sites.
Simultaneously, the egg's membrane potential depolarizes (the fast block to polyspermy, lasting seconds), followed by the permanent slow block from the zona reaction.

Pronuclear fusion and the zygote

After sperm entry, the egg completes meiosis II (it had been arrested at metaphase II), extruding the second polar body. The sperm nucleus decondenses (its protamines are replaced by histones from the oocyte cytoplasm) and forms the male pronucleus. The egg's nucleus becomes the female pronucleus. Each pronucleus contains 23 chromosomes (1N, 2C -- replicated DNA). The two pronuclei migrate toward each other, their nuclear envelopes break down, and the chromosomes align on the first mitotic spindle. The zygote is now 2N, 4C and immediately undergoes its first cleavage division.

Cleavage and blastocyst formation

Cleavage is a series of rapid mitotic divisions without growth. The zygote subdivides its cytoplasm into progressively smaller cells called blastomeres:

2-cell stage (~30 hours post-fertilization)
4-cell stage (~48 hours)
8-cell stage (~72 hours)
Morula (16--32 cells, ~day 3--4): a solid ball of cells still enclosed in the zona pellucida
Compaction (at the 8--16 cell stage): blastomeres flatten against each other and form tight junctions, establishing inside-outside polarity
Blastocyst (~day 4--5): a fluid-filled cavity (blastocoel) forms, and the embryo differentiates into:
- Inner cell mass (ICM): a cluster of cells at one pole that will become the embryo proper (source of embryonic stem cells).
- Trophoblast: the outer epithelial layer that will form the fetal contribution to the placenta.
Hatching (~day 5--6): the blastocyst escapes from the zona pellucida, enabling implantation.

Implantation (days 6--12)

Implantation occurs in the fundus or posterior wall of the uterine body. The process:

Apposition (day 6): the blastocyst contacts the endometrial surface.
Adhesion (day 6--7): trophoblast cells adhere to the endometrial epithelium via adhesion molecules (integrins, selectins, heparan sulfate proteoglycans).
Invasion (days 7--12): the trophoblast differentiates into two layers:
- Cytotrophoblast: an inner layer of discrete, proliferating mononuclear cells.
- Syncytiotrophoblast: an outer multinucleated mass formed by fusion of cytotrophoblast cells. The syncytiotrophoblast invades the endometrium enzymatically, eroding into maternal blood vessels and glands.

The endometrial response (decidualization) involves stromal cells transforming into large, glycogen-rich decidual cells under the influence of progesterone. The decidua provides nutritive support, regulates trophoblast invasion, and protects the endometrium from excessive penetration.

HCG signaling and the corpus luteum

Human chorionic gonadotropin (HCG) is a glycoprotein hormone structurally similar to LH (they share an identical alpha subunit; the beta subunit differs). HCG is produced by the syncytiotrophoblast and has one critical function in early pregnancy: rescue of the corpus luteum.

Without pregnancy, the corpus luteum degenerates after ~14 days (the luteal phase), progesterone drops, and the endometrium is shed. HCG binds to the LH receptor on luteal cells, maintaining luteal function and progesterone/estrogen secretion beyond its normal lifespan. This progesterone maintains the secretory endometrium and suppresses uterine contractions, allowing the embryo to implant and develop.

HCG levels:

Detectable in maternal serum ~day 10 post-fertilization
Doubles approximately every 48 hours in early normal pregnancy
Peaks at 8--11 weeks (~100,000 mIU/mL)
Declines to a plateau for the remainder of pregnancy

The luteal-placental shift occurs at 10--12 weeks: the placenta becomes the primary source of progesterone, and the corpus luteum is no longer essential.

Placental formation

The placenta is a fetomaternal organ with two components:

Fetal component (chorion):

Chorionic villi are the functional units. Primary villi (solid trophoblast cores) form by day 12--14, then develop mesenchymal cores (secondary villi), and finally develop fetal blood vessels (tertiary villi) by day 21.
Each villus has a core of fetal capillaries surrounded by cytotrophoblast and an outer layer of syncytiotrophoblast.
The syncytiotrophoblast is the primary barrier for maternal-fetal exchange.

Maternal component (decidua basalis):

Spiral artery remodeling: cytotrophoblast cells invade maternal spiral arteries, replacing the endothelial lining and muscular wall, converting them from high-resistance to low-resistance, high-capacity vessels. This ensures adequate blood flow to the intervillous space. Remodeling is completed by 20--24 weeks.
The intervillous space is filled with maternal blood bathing the chorionic villi. Exchange occurs across the syncytiotrophoblast barrier.

Placental exchange (no direct mixing of fetal and maternal blood):

Substance	Direction	Mechanism
Oxygen (O2)	Maternal -> Fetal	Simple diffusion (concentration gradient)
Carbon dioxide (CO2)	Fetal -> Maternal	Simple diffusion
Glucose	Maternal -> Fetal	Facilitated diffusion (GLUT1, GLUT3)
Amino acids	Maternal -> Fetal	Active transport (amino acid transporters)
Fatty acids	Maternal -> Fetal	Diffusion and protein-mediated transport
Antibodies (IgG)	Maternal -> Fetal	Receptor-mediated transcytosis (FcRn receptor)
Urea/creatinine	Fetal -> Maternal	Simple diffusion
Iron	Maternal -> Fetal	Receptor-mediated endocytosis (transferrin)

Maternal cardiovascular adaptations to pregnancy

The maternal circulatory system undergoes profound changes to support the growing fetus:

Blood volume increases by 40--50% (plasma volume > red cell mass increase, causing physiological anemia of pregnancy).
Cardiac output increases by 30--50% (peaks at 20--24 weeks), driven by increased stroke volume and heart rate.
Systemic vascular resistance decreases (progesterone-mediated vasodilation, low-resistance placental circuit).
Glomerular filtration rate (GFR) increases by ~50%, enhancing renal clearance of creatinine, urea, and uric acid.
Minute ventilation increases by 40--50% (progesterone stimulates respiratory centers), causing a respiratory alkalosis compensated by renal bicarbonate excretion.

Key results Intermediate+

Result 1 (Polyspermy is prevented at two levels). The fast block (membrane depolarization, lasting seconds) and the slow block (cortical reaction and zona hardening, lasting permanently) together ensure that only one sperm fertilizes the egg. If two sperm penetrate (dispermy), the resulting triploid (3N = 69 chromosomes) zygote is almost always non-viable. Triploidy accounts for approximately 2% of all conceptions and is a common finding in first-trimester miscarriages.

Result 2 (HCG doubling time is a clinical indicator). In a normal intrauterine pregnancy, serum HCG doubles approximately every 48 hours in the first 6--7 weeks. A rise of less than 53% in 48 hours is strongly suggestive of an ectopic pregnancy (implantation outside the uterus, most commonly in the fallopian tube). Abnormally high HCG may indicate a multiple gestation or molar pregnancy. Serial HCG measurement is one of the most important tools in early pregnancy evaluation.

Result 3 (Spiral artery remodeling is the key to successful placentation). Normal placentation requires cytotrophoblast invasion to a depth of the inner third of the myometrium, converting spiral arteries into dilated, low-resistance vessels. Failure of this remodeling underlies preeclampsia -- a syndrome of new-onset hypertension and proteinuria after 20 weeks of gestation. Poorly remodeled arteries produce placental ischemia, releasing anti-angiogenic factors (sFlt-1, soluble endoglin) into the maternal circulation that cause widespread endothelial dysfunction.

Exercise 1

Exercise 1 (medium, short answer).

Describe the cortical reaction. What triggers it, what cellular events occur, and what is the result?

Hint

The cortical reaction is triggered by sperm-egg fusion and a calcium wave. Consider what the cortical granules release and how this changes the zona pellucida.

Answer

The cortical reaction is triggered when the first sperm fuses with the egg plasma membrane. Sperm entry activates a G-protein/PLC pathway in the egg, generating IP3, which causes a massive wave of calcium release from the endoplasmic reticulum that propagates across the entire oocyte over 2--3 minutes. This calcium surge causes cortical granules -- membrane-bound vesicles at the egg periphery -- to fuse with the plasma membrane and release their enzymatic contents into the perivitelline space. The cortical granule enzymes (including ovastacin, a zinc metalloprotease) cleave ZP2 and modify ZP3 in the zona pellucida, destroying sperm-binding sites and causing the zona to harden (the zona reaction). This constitutes the slow block to polyspermy and is irreversible: no additional sperm can bind to or penetrate the zona pellucida.

Exercise 2

Exercise 2 (medium, short answer).

A woman has a serum HCG level of 1,200 mIU/mL on Monday. On Wednesday (48 hours later), the level is 1,500 mIU/mL. Is this rise consistent with a normal intrauterine pregnancy? What is the primary concern?

Hint

In a normal pregnancy, HCG should rise by at least 53% (roughly double) every 48 hours in early pregnancy. Calculate the percent increase.

Answer

The percent increase is (1,500 - 1,200) / 1,200 = 25%, which is well below the expected minimum rise of 53% in 48 hours. This inadequate rise is not consistent with a normal intrauterine pregnancy. The primary concern is an ectopic pregnancy, in which the embryo implants outside the uterus (most commonly in the fallopian tube). The abnormal HCG rise reflects the inadequate trophoblast mass of an ectopic gestation. Transvaginal ultrasound should be performed to locate the pregnancy. If an intrauterine gestational sac is not visible and HCG is above the discriminatory zone (~1,500--2,000 mIU/mL for transvaginal ultrasound), ectopic pregnancy is highly suspected. Subnormal HCG rise can also indicate a failing (non-viable) intrauterine pregnancy, but ectopic pregnancy must be ruled out first because it is a life-threatening emergency.

Exercise 3

Exercise 3 (medium, short answer).

Explain why maternal blood does not clot in the intervillous space of the placenta despite being in direct contact with fetal trophoblast tissue.

Hint

Consider what the syncytiotrophoblast produces to prevent coagulation and how the placenta maintains blood fluidity in the intervillous space.

Answer

The syncytiotrophoblast produces several anticoagulant factors that prevent clotting in the intervillous space:

Thrombomodulin on the trophoblast surface binds thrombin and activates protein C, an anticoagulant that inactivates factors Va and VIIIa.
Tissue factor pathway inhibitor (TFPI) is expressed by trophoblast cells and blocks the extrinsic coagulation pathway.
Heparan sulfate proteoglycans on the trophoblast surface enhance antithrombin III activity.
Plasminogen activators (tPA) are expressed, promoting fibrinolysis.

These mechanisms ensure that maternal blood remains fluid in the intervillous space, allowing continuous gas and nutrient exchange. However, the coagulation system is still poised to respond: after delivery, the separation of the placenta exposes the decidual wound surface, and rapid vasoconstriction combined with local coagulation prevents postpartum hemorrhage.

Advanced treatment Master

Ectopic pregnancy

Ectopic pregnancy occurs when the blastocyst implants outside the uterine cavity. Approximately 97% implant in the fallopian tube (95% ampullary, 2.5% isthmic, 0.5% fimbrial); rare sites include the ovary, cervix, cesarean scar, and abdomen. Incidence is approximately 1--2% of all pregnancies. Risk factors include prior pelvic inflammatory disease (salpingitis, often from chlamydia), prior tubal surgery, endometriosis, smoking, and assisted reproductive technology. IUD use prevents intrauterine pregnancy but does not prevent ectopic implantation if fertilization occurs.

Diagnosis relies on serial HCG (subnormal rise), transvaginal ultrasound (adnexal mass, free fluid in the pouch of Douglas), and clinical presentation (amenorrhea, vaginal bleeding, unilateral pelvic pain). Tubal rupture causes hemoperitoneum and is a surgical emergency. Treatment options: methotrexate (for stable, unruptured ectopics with HCG <5,000 and no fetal cardiac activity) or laparoscopic salpingostomy/salpingectomy.

Implantation failure and recurrent implantation failure

Successful implantation requires a receptive endometrium (a narrow window of receptivity, days 20--24 of the menstrual cycle, corresponding to days 6--10 post-ovulation), a euploid blastocyst with normal developmental competence, and synchronized cross-talk between embryo and endometrium. Implantation failure is the most common reason IVF cycles do not result in pregnancy.

Recurrent implantation failure (RIF) is defined as failure to achieve pregnancy after transfer of >=10 high-quality embryos across >=2 IVF cycles. Causes include: chromosomal abnormalities in the embryo (the most common cause, especially with advancing maternal age), thin endometrium (<7 mm), impaired endometrial receptivity (altered pinopode formation, abnormal cytokine profiles), thrombophilias (antiphospholipid syndrome, factor V Leiden), immunological factors (elevated uterine NK cells, anti-thyroid antibodies), and male factor (sperm DNA fragmentation >30%). Treatment strategies include preimplantation genetic testing for aneuploidy (PGT-A), endometrial receptivity array (ERA) timing, hysteroscopic evaluation, and immunomodulatory therapy (intralipid, IVIG, corticosteroids) in selected cases.

HCG dynamics and clinical interpretation

HCG measurement has several important clinical applications beyond pregnancy confirmation:

Discriminatory zone: when serum HCG exceeds 1,500--2,000 mIU/mL, a gestational sac should be visible on transvaginal ultrasound. If no intrauterine pregnancy is seen at this level, ectopic pregnancy is suspected.
Doubling time: normal doubling time is 48 hours (range 1.2--2.5 days). A plateau or decline suggests a non-viable pregnancy. A rise <53% in 48 hours suggests ectopic pregnancy.
Molar pregnancy: HCG levels are markedly elevated (>100,000 mIU/mL at 6--8 weeks) with no identifiable fetus on ultrasound. Complete moles (46,XX, androgenetic -- all chromosomes from the father) and partial moles (triploid, 69 chromosomes) carry a risk of progression to choriocarcinoma (2--4% after complete mole, <1% after partial mole).
Down syndrome screening: HCG (specifically free beta-HCG) is a component of the second-trimester triple/quad screen. Elevated HCG at 15--20 weeks is associated with trisomy 21.

Placenta previa and placental abruption

Placenta previa occurs when the placenta implants in the lower uterine segment, covering or adjacent to the internal cervical os. Classification: complete (covers the os), partial, marginal (edge at the os), or low-lying (within 2 cm of the os). Incidence is approximately 0.3--0.5% of pregnancies at term. Risk factors include prior cesarean delivery, multiparity, advanced maternal age, and smoking. Presentation is classically painless bright red vaginal bleeding in the second or third trimester. Management: pelvic rest, hospitalization for bleeding episodes, and planned cesarean delivery (for complete previa) at 36--37 weeks after amniocentesis for fetal lung maturity, or earlier if hemorrhage occurs. Placenta previa with prior cesarean section carries a high risk of placenta accreta spectrum (abnormal trophoblast invasion beyond the decidua into the myometrium or beyond), which is a major cause of peripartum hysterectomy.

Placental abruption is premature separation of a normally implanted placenta before delivery. Incidence is approximately 0.5--1% of pregnancies. Risk factors include hypertension (chronic or preeclampsia), trauma, smoking, cocaine use, multiparity, and prior abruption. Presentation includes painful vaginal bleeding, uterine tenderness, and fetal distress. Concealed abruption (blood trapped behind the placenta) can be particularly dangerous because external bleeding may be minimal while retroplacental hemorrhage is extensive. Complications include fetal hypoxia and death, maternal hemorrhage and DIC (disseminated intravascular coagulation from release of thromboplastin into the maternal circulation), and Couvelaire uterus (blood infiltration into the myometrium). Management depends on gestational age and severity: expectant management for mild cases remote from term, immediate delivery for severe cases.

Preeclampsia

Preeclampsia is a multisystem disorder characterized by new-onset hypertension (>=140/90 mmHg) and proteinuria (>=300 mg/24 hours) or end-organ dysfunction after 20 weeks of gestation. It affects 2--8% of pregnancies worldwide and is a leading cause of maternal and perinatal morbidity and mortality.

The pathogenesis begins with abnormal cytotrophoblast invasion and incomplete spiral artery remodeling in early pregnancy. The resulting placental ischemia releases anti-angiogenic factors into the maternal circulation:

Soluble fms-like tyrosine kinase 1 (sFlt-1): a truncated form of the VEGF receptor that acts as a circulating antagonist, binding and neutralizing VEGF and PlGF (placental growth factor). This causes widespread maternal endothelial dysfunction.
Soluble endoglin (sEng): inhibits TGF-beta signaling in endothelial cells, impairing nitric oxide-mediated vasodilation.

The consequences of endothelial dysfunction include: hypertension (from vasoconstriction and increased sensitivity to angiotensin II), proteinuria (from glomerular endotheliosis), cerebral edema and seizures (eclampsia), HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), pulmonary edema, and fetal growth restriction (from compromised placental perfusion).

Risk factors: nulliparity, prior preeclampsia, chronic hypertension, pregestational diabetes, antiphospholipid syndrome, multiple gestation, obesity, and advanced maternal age.

The sFlt-1 ratio has emerged as a diagnostic and prognostic biomarker. A ratio <38 effectively rules out preeclampsia within the next week (negative predictive value >99%). A ratio >85 in early preterm pregnancy confirms the diagnosis.

Management: the only definitive treatment is delivery of the placenta. For severe preeclampsia at >=34 weeks, delivery is recommended. For mild preeclampsia, expectant management until 37 weeks is standard. Magnesium sulfate is used for seizure prophylaxis in severe preeclampsia and eclampsia. Low-dose aspirin (81--162 mg/day), initiated before 16 weeks, reduces preeclampsia risk by 50--70% in high-risk women.

Gestational trophoblastic disease

Gestational trophoblastic disease (GTD) encompasses a spectrum of tumors derived from trophoblastic tissue:

Complete hydatidiform mole: androgenetic diploid (46,XX or 46,XY) conceptus with no embryo. All nuclear DNA is paternally derived (empty egg fertilized by one or two sperm). The trophoblast hyperproliferates, producing swollen, grape-like chorionic villi ("cluster of grapes" appearance on ultrasound). HCG is markedly elevated. Malignant transformation occurs in 15--20% of cases (invasive mole or choriocarcinoma).
Partial hydatidiform mole: triploid (69,XXX or 69,XXY) conceptus with a malformed embryo. One set of maternal chromosomes plus two sets of paternal chromosomes. Malignant transformation in <5%.
Invasive mole: molar tissue invades the myometrium. Retained molar tissue after evacuation; persistently elevated HCG.
Choriocarcinoma: a highly malignant tumor of cytotrophoblast and syncytiotrophoblast that metastasizes hematogenously to lungs, brain, liver, and vagina. HCG is the tumor marker. Choriocarcinoma can occur after any pregnancy (mole, normal pregnancy, miscarriage, ectopic) but is most common after molar pregnancy. Treatment with methotrexate-based chemotherapy is highly effective, even with metastatic disease (cure rates >90%).
Placental-site trophoblastic tumor (PSTT): a rare variant derived from intermediate trophoblast, producing low levels of HCG. More indolent but chemotherapy-resistant; may require hysterectomy.

Embryonic stem cells and the inner cell mass

The inner cell mass (ICM) of the blastocyst gives rise to all three germ layers (ectoderm, mesoderm, endoderm) of the embryo proper. When isolated and cultured, ICM cells can be maintained indefinitely as embryonic stem cells (ESCs), which are:

Pluripotent: capable of differentiating into any cell type of the three germ layers.
Self-renewing: capable of unlimited proliferation while maintaining pluripotency.
Characterized by expression of transcription factors OCT4, NANOG, and SOX2, which form the core pluripotency network.

ESCs were first isolated from mouse blastocysts by Martin Evans and Matthew Kaufman (1981), and from human blastocysts by James Thomson (1998). The ethical controversy surrounding human ESC derivation (which requires destruction of the blastocyst) led to the development of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka (2006), who reprogrammed adult fibroblasts to a pluripotent state by introducing four transcription factors (OCT4, SOX2, KLF4, c-MYC). iPSCs are functionally equivalent to ESCs but avoid the ethical issues of embryo destruction. iPSC technology earned Yamanaka the Nobel Prize in 2012.

Preimplantation genetic testing

Preimplantation genetic testing (PGT) is performed on embryos created through IVF before transfer to the uterus:

PGT-A (for aneuploidy): biopsy of 5--10 trophectoderm cells from a day-5 blastocyst, followed by comprehensive chromosomal screening (array CGH, SNP array, or next-generation sequencing). PGT-A improves implantation rates and reduces miscarriage rates in women over 35 by selecting euploid embryos for transfer. It does not increase the overall number of euploid embryos available (it can only select among those produced).
PGT-M (for monogenic disorders): targeted testing for specific genetic conditions (cystic fibrosis, Huntington disease, BRCA mutations) in families with known pathogenic variants.
PGT-SR (for structural rearrangements): testing for unbalanced chromosomal arrangements in parents carrying balanced translocations or inversions.

IVF and ICSI procedures

In vitro fertilization (IVF): developed by Robert Edwards and Patrick Steptoe, resulting in the birth of Louise Brown in 1978. Current protocol involves ovarian stimulation with FSH (producing multiple follicles), prevention of premature LH surge with GnRH agonist or antagonist, final oocyte maturation with HCG or GnRH agonist trigger, transvaginal ultrasound-guided oocyte retrieval 34--36 hours later, fertilization by conventional IVF (co-incubation of oocytes with ~100,000 motile sperm) or ICSI, embryo culture to day 3 (cleavage stage) or day 5--6 (blastocyst), and transfer of 1--2 embryos. Excess embryos are cryopreserved by vitrification.

Intracytoplasmic sperm injection (ICSI): developed by Gianpiero Palermo and colleagues in 1992. A single sperm is selected, immobilized, and injected directly through the zona pellucida and oolemma into the oocyte cytoplasm using a micromanipulator. ICSI bypasses all natural sperm selection barriers (capacitation, zona binding, acrosome reaction, membrane fusion). It is indicated for severe male factor infertility, prior fertilization failure with conventional IVF, and use of surgically retrieved sperm. Fertilization rates are 70--80% per oocyte. Concerns include slightly increased rates of sex chromosome aneuploidies in ICSI offspring (related to the underlying male factor rather than the technique itself) and the absence of natural sperm selection.

Epigenetic reprogramming

After fertilization, the zygote undergoes extensive epigenetic reprogramming:

Active demethylation of the paternal genome occurs rapidly in the first cell cycle (mediated by TET3 oxidase, which hydroxylates 5-methylcytosine).
Passive demethylation of the maternal genome occurs through dilution of methylation marks during subsequent cleavage divisions (DNMT1 is excluded from the nucleus).
By the blastocyst stage, global DNA methylation is at its lowest point.
Genomic imprints (parent-of-origin-specific epigenetic marks at ~100 genes) are protected from this wave of demethylation by special imprinting control regions (ICRs). Aberrant imprinting causes disorders such as Beckwith-Wiedemann syndrome (paternal uniparental disomy or loss of maternal imprinting at 11p15) and Prader-Willi/Angelman syndromes (15q11-q13).
X-chromosome inactivation occurs randomly in the ICM (each cell independently silences one X) but is imprinted (paternal X silenced) in the trophectoderm lineage. XIST RNA coats the inactive X chromosome, recruiting silencing machinery.

Twinning

Dizygotic (fraternal) twins result from fertilization of two separate oocytes by two separate sperm. They are genetically as similar as any siblings (sharing ~50% of genes). Incidence varies by ethnicity and increases with maternal age, parity, and use of fertility drugs. Dizygotic twinning has two placentas (dichorionic) and two amniotic sacs (diamniotic).

Monozygotic (identical) twins result from splitting of a single embryo. The timing of splitting determines the placentation:

Timing of splitting	Placentation	Amnion/Chorion	Frequency
Day 0--4 (pre-blastocyst)	Dichorionic, diamniotic	Two of each	~30% of MZ twins
Day 4--8 (early blastocyst)	Monochorionic, diamniotic	Shared chorion, two amnions	~70% of MZ twins
Day 8--12 (post-ICM)	Monochorionic, monoamniotic	Shared both	~1--2% of MZ twins
Day 13+ (incomplete splitting)	Conjoined twins	Shared body parts	Extremely rare

Monochorionic twins share placental vascular connections (anastomoses) that can lead to twin-to-twin transfusion syndrome (TTTS): arteriovenous anastomoses cause unidirectional blood flow from the donor twin (small, anemic, oligohydramnios) to the recipient twin (large, polycythemic, polyhydramnios, high-output cardiac failure). Treatment is fetoscopic laser ablation of the anastomotic vessels.

Exercise 4

Exercise 4 (hard, analysis).

A 29-year-old woman at 32 weeks of gestation presents with new-onset headache, visual disturbances (scintillating scotomata), and blood pressure of 162/108 mmHg. Urine protein-to-creatinine ratio is 1.2 (equivalent to >1 g/24 hours). Platelets are 95,000/microL. AST is 120 U/L, ALT is 98 U/L.

(a) What is the diagnosis? (b) Explain the pathogenesis, starting from the early pregnancy event that initiates this condition. (c) What is the appropriate management? (d) What laboratory finding would distinguish this from a complete hydatidiform mole, and why?

Hint

The combination of new-onset hypertension, proteinuria, and end-organ dysfunction (low platelets, elevated liver enzymes) after 20 weeks is diagnostic. The pathogenesis begins with abnormal placentation. Consider what biomarkers distinguish preeclampsia from molar pregnancy.

Answer

(a) Severe preeclampsia with HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets). The criteria for severe preeclampsia are met (BP >=160/110, symptoms of end-organ involvement including headache and visual disturbances). The thrombocytopenia and elevated transaminases fulfill HELLP criteria.

(b) Pathogenesis:

Stage 1 (early pregnancy, 10--20 weeks): Abnormal cytotrophoblast invasion fails to fully remodel maternal spiral arteries. The vessels remain narrow and high-resistance instead of becoming dilated and low-resistance.
Stage 2 (clinical phase, >20 weeks): Placental ischemia from poor perfusion triggers release of anti-angiogenic factors, primarily sFlt-1 (soluble fms-like tyrosine kinase 1) and soluble endoglin. sFlt-1 binds and neutralizes VEGF and PlGF (placental growth factor), depriving maternal endothelial cells of these pro-angiogenic signals.
Stage 3 (end-organ damage): Widespread endothelial dysfunction causes vasoconstriction (hypertension), increased vascular permeability (edema), glomerular endotheliosis (proteinuria), microangiopathic hemolysis (schistocytes, elevated LDH), hepatic sinusoidal obstruction (elevated transaminases, periportal hemorrhage and necrosis), and platelet activation and consumption (thrombocytopenia). Cerebral vasospasm and edema cause headache and visual disturbances; severe cases progress to eclamptic seizures.

(c) Magnesium sulfate for seizure prophylaxis (loading dose 4--6 g IV, then 1--2 g/hr continuous infusion) and delivery as the definitive treatment. At 32 weeks, corticosteroids (betamethasone 12 mg IM x 2 doses, 24 hours apart) are given for fetal lung maturation. If the maternal condition is stable enough for a 48-hour delay, delivery can be planned after steroid completion. If the woman deteriorates (eclampsia, DIC, pulmonary edema, uncontrolled hypertension, or non-reassuring fetal status), immediate delivery is indicated regardless of gestational age. Blood pressure control with IV labetalol or hydralazine to maintain BP <160/110.

(d) HCG level. A complete hydatidiform mole produces markedly elevated HCG (>100,000 mIU/mL at 6--8 weeks) with no identifiable fetus on ultrasound. In preeclampsia, HCG may be modestly elevated but not to the extreme levels seen in molar pregnancy. Additionally, a molar pregnancy would show the characteristic "cluster of grapes" appearance on ultrasound with no gestational sac or fetus. Preeclampsia, by contrast, has a normally developing fetus. Of note, preeclampsia can occur with molar pregnancy (the trophoblastic tissue produces anti-angiogenic factors and can trigger the same cascade), but the ultrasound appearance and HCG level are diagnostic.

Exercise 5

Exercise 5 (hard, analysis).

A couple undergoing IVF has 8 blastocysts available. PGT-A testing reveals: 3 euploid, 4 aneuploid (2 with trisomy 21, 1 with monosomy X, 1 with trisomy 16), and 1 mosaic (mix of euploid and aneuploid cells).

(a) Which embryos are transferable? Explain the reasoning for the aneuploid embryos. (b) The patient asks about the mosaic embryo. What counseling should be provided? (c) If a single euploid blastocyst is transferred, what is the approximate implantation rate compared with an untested blastocyst? Why? (d) What is the biological explanation for the high rate of aneuploidy (50%) in this cohort?

Hint

Consider the viability of different aneuploidies: trisomy 21 is compatible with life, monosomy X causes Turner syndrome, trisomy 16 is lethal. Mosaic embryos have intermediate outcomes. The aneuploidy rate increases with maternal age due to meiotic errors in oocytes.

Answer

(a) The 3 euploid embryos are transferable. The aneuploid embryos are not transferred:

Trisomy 21 results in Down syndrome (live-born with intellectual disability, congenital heart defects, and other anomalies). While compatible with life, PGT-A identifies these embryos to allow the couple to decide whether to transfer or discard them. Most clinics do not transfer known trisomy 21 embryos.
Monosomy X (45,X) results in Turner syndrome, which is compatible with life but associated with ovarian dysgenesis, short stature, cardiovascular anomalies (bicuspid aortic valve, coarctation), and infertility. Not typically transferred in PGT-A programs.
Trisomy 16 is the most common trisomy in first-trimester miscarriages and is lethal in full form -- no live-born infants with full trisomy 16 have been reported. This embryo would inevitably miscarry if transferred.

(b) Mosaic embryos (containing both euploid and aneuploid cell lines) represent a gray zone in PGT-A. Counseling points:

Mosaic embryos can result in healthy live births, likely because the euploid cells have a proliferative advantage during development and the aneuploid cell line may be self-corrected or outgrown.
The risk of miscarriage is higher than with euploid embryos (~15--20% vs. ~5--10%).
The risk of chromosomal abnormality in the offspring is low but not zero.
Mosaic embryos are typically transferred after euploid embryos have been exhausted.
Current guidelines (ASRM, 2023) allow transfer of mosaic embryos with informed consent when no euploid embryos are available.
The specific type of mosaicism matters: mosaicism for chromosomes compatible with life (13, 18, 21, X, Y) carries more risk than mosaicism for lethal aneuploidies.

(c) A single euploid blastocyst has an implantation rate of approximately 55--70% per transfer, compared with approximately 30--40% for an untested blastocyst in a woman of similar age. The difference reflects selection bias: PGT-A eliminates aneuploid embryos (which account for the majority of implantation failures and miscarriages), so every transferred embryo has normal chromosomes and a high probability of implanting. However, PGT-A does not improve the total number of pregnancies per retrieval -- it increases the implantation rate per transfer and reduces the time to pregnancy and the miscarriage rate.

(d) The 50% aneuploidy rate is explained by maternal age-related meiotic nondisjunction in oocytes. The most common source of aneuploidy in human embryos is meiosis I errors in the oocyte. The cohesin proteins that hold homologous chromosome pairs together are established during fetal development and must persist for decades until ovulation. With advancing maternal age, cohesin deteriorates, leading to premature separation of homologs and nondisjunction. The maternal age effect is dramatic: at age 25, approximately 30% of oocytes are aneuploid; at age 40, approximately 70--80%. Paternal meiotic errors contribute only about 5--10% of aneuploidies. Mitotic errors after fertilization (mosaicism) account for some additional cases.

Connections Master

Gametogenesis 18.09.02 pending. Fertilization directly continues the story from gametogenesis. The sperm produced by spermatogenesis must undergo capacitation in the female tract; the secondary oocyte released at ovulation completes meiosis II only upon sperm entry. The meiotic errors discussed in 18.09.02 pending (nondisjunction increasing with maternal age) produce the aneuploid embryos screened by PGT-A.
Reproductive biology 18.09.01. This unit extends the reproductive biology survey, detailing the events that follow ovulation: fertilization, implantation, and the establishment of pregnancy. The corpus luteum, introduced in 18.09.01 as the post-ovulatory structure, is here rescued by HCG and maintained through the first trimester.
Endocrine hormones and regulation 18.07.01. HCG exploits the same LH receptor as luteinizing hormone, illustrating hormone-receptor specificity and the principle that structurally similar hormones can activate the same receptor. The maternal cardiovascular adaptations to pregnancy (increased cardiac output, blood volume, GFR) demonstrate the endocrine system's ability to orchestrate systemic physiological changes.
Immunology 18.10.01. The fetus is a semi-allograft (sharing half its antigens with the mother) yet is not rejected. Maternal-fetal immune tolerance involves regulatory T cells, indoleamine 2,3-dioxygenase (IDO) expression in the placenta, HLA-G expression by trophoblast (a non-classical MHC class I molecule that inhibits NK cell killing), and complement regulation. The syncytiotrophoblast lacks classical MHC class I and class II expression, avoiding T-cell recognition. Failure of maternal-fetal tolerance may contribute to recurrent pregnancy loss and preeclampsia.
Development 18.11.01. Cleavage, blastocyst formation, and implantation are the earliest events in the developmental program covered in 18.11.01. The inner cell mass gives rise to the three germ layers; the trophoblast gives rise to the extraembryonic membranes. Epigenetic reprogramming (demethylation, imprint maintenance, X-inactivation) establishes the developmental potential of the early embryo.
Cardiovascular physiology 18.02.01. The maternal hemodynamic adaptations to pregnancy (40--50% increase in blood volume, 30--50% increase in cardiac output, decreased systemic vascular resistance) stress-test the cardiovascular system. Pre-existing cardiac conditions (e.g., mitral stenosis, peripartum cardiomyopathy) may decompensate under the volume load of pregnancy.

Historical & philosophical context Master

The study of fertilization has its origins in the earliest days of microscopy. Antonie van Leeuwenhoek first observed spermatozoa in 1677 and, along with Nicolaas Hartsoeker, proposed that each sperm contained a preformed miniature human (the "homunculus" theory). This spermist preformationism competed with ovist preformationism (championed by Marcello Malpighi and others), which held that the egg contained the preformed organism. Both theories were refuted by the epigenetic view, most persuasively argued by Caspar Friedrich Wolff in 1759, who demonstrated that embryonic structures arise progressively through development.

The actual event of fertilization was not directly observed until the 19th century. Karl Ernst von Baer discovered the mammalian ovum in 1827. Oscar Hertwig observed sperm entering a sea urchin egg in 1876 and described the fusion of the two pronuclei -- the first direct evidence that both parents contribute nuclear material equally. The role of the sperm in activating the egg (beyond delivering chromosomes) was not understood until the 20th century, when the calcium wave was discovered.

The acrosome reaction was first described by Jean Clark in 1936 in invertebrate sperm, and the zona pellucida glycoprotein ZP3 was identified as the sperm receptor by Paul Wassarman and colleagues in the 1980s. The sperm-egg fusion proteins IZUMO1 and JUNO were not identified until 2005 and 2014, respectively, by Masaru Okabe and Gavin Wright's groups.

The discovery of HCG dates to 1927, when Selmar Aschheim and Bernhard Zondek found that urine from pregnant women contained a gonad-stimulating substance (originally called "prolan"). The Aschheim-Zondek test was the first reliable pregnancy test, using injection of urine into immature mice and examining the ovarian response. Immunological pregnancy tests using anti-HCG antibodies were developed in the 1960s, and the modern home pregnancy test (using monoclonal antibodies in a lateral flow format) was introduced in 1988.

IVF's history is intertwined with the history of embryonic stem cells. Robert Edwards, working with Patrick Steptoe, achieved the first human IVF pregnancy in 1978 (Louise Brown). Edwards had earlier shown, with Robin Cole in 1965, that mouse blastocysts could give rise to embryonic stem cell cultures, and he recognized the potential of the inner cell mass as a source of pluripotent cells. In his 2001 Nature article "IVF and the history of stem cells," Edwards traced the intellectual lineage from IVF to ESCs to regenerative medicine. James Thomson isolated human ESCs in 1998, and Shinya Yamanaka produced iPSCs in 2006.

The placenta, long considered a passive conduit, is now recognized as a highly active endocrine organ -- the only organ composed of tissues from two individuals. The discovery of its role in preeclampsia pathogenesis (through sFlt-1 and PlGF) by S. Ananth Karumanchi and colleagues in the 2000s transformed understanding of this ancient disease, first described by Hippocrates as "water and convulsions" in pregnancy. The shift from a "maternal disease" model to a "placental disease" model exemplifies how understanding organ-level pathophysiology can redefine clinical disease categories.

The ethical dimensions of early human development research remain profound. The 14-day rule -- a limit on culturing human embryos beyond 14 days post-fertilization, established by the Warnock Committee in 1984 and adopted internationally -- reflects a societal compromise about the moral status of the early embryo. Recent advances in embryo culture (Magdalena Zernicka-Goetz's group maintained human embryos in vitro to day 13 in 2016) have reignited debate about whether the rule should be extended.

Bibliography Master

Sherwood, L., Human Physiology: From Cells to Systems, 9th ed. (Cengage, 2016), Ch. 20.
Silverthorn, D. U., Human Physiology: An Integrated Approach, 8th ed. (Pearson, 2019), Ch. 26.
Guyton, A. C. & Hall, J. E., Textbook of Medical Physiology, 14th ed. (Elsevier, 2021), Ch. 82--83.
Edwards, R. G., "IVF and the history of stem cells", Nature 413 (2001), 349--351.
Johnson, M. H., Essential Reproduction, 8th ed. (Wiley-Blackwell, 2018), Ch. 9--11.
Palermo, G. D., Joris, H., Devroey, P. & Van Steirteghem, A. C., "Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte", Lancet 340 (1992), 17--18.
Inoue, N., Ikawa, M., Isotani, A. & Okabe, M., "The immunoglobulin superfamily protein Izumo is required for sperm to fuse with eggs", Nature 434 (2005), 234--238.
Bianchi, E., Doe, B., Goulding, D. & Wright, G. J., "Juno is the egg Izumo receptor and is essential for mammalian fertilization", Nature 508 (2014), 483--487.
Karumanchi, S. A. & Granger, J. P., "Preeclampsia: a problem with the placenta", in Hypertension: A Companion to Braunwald's Heart Disease, 3rd ed. (Elsevier, 2023), Ch. 27.
Levy, R., "The 14-day rule for human embryo research: history and future", Hum. Reprod. 37 (2022), 1339--1345.
Takahashi, K. & Yamanaka, S., "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors", Cell 126 (2006), 663--676.
Thomson, J. A. et al., "Embryonic stem cell lines derived from human blastocysts", Science 282 (1998), 1145--1147.
The American College of Obstetricians and Gynecologists, "Gestational hypertension and preeclampsia: ACOG Practice Bulletin No. 222", Obstet. Gynecol. 135 (2020), e237--e260.
The Practice Committee of the American Society for Reproductive Medicine, "Guidance on the limits to the number of embryos to transfer: a committee opinion", Fertil. Steril. 116 (2021), 703--712.
Zernicka-Goetz, M., "The dance of the two parents: how the egg and sperm nuclei merge to form a new life", in The Dance of Life: The New Science of How a Single Cell Becomes a Human Being (Scribner, 2020).